W. Zhang
About
W. Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, W. Zhang has authored 18 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in W. Zhang's work include Colorectal Cancer Treatments and Studies (10 papers), Gastric Cancer Management and Outcomes (4 papers) and Lung Cancer Treatments and Mutations (4 papers). W. Zhang is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Gastric Cancer Management and Outcomes (4 papers) and Lung Cancer Treatments and Mutations (4 papers). W. Zhang collaborates with scholars based in United States, Germany and Austria. W. Zhang's co-authors include Dongyun Yang, Heinz‐Josef Lenz, Frank LaCreta, David W. Boulton, Sreeneeranj Kasichayanula, Marc Pfister, Xuejun Liu, Anthony B. El-Khoueiry, T. Li and Steven C. Griffen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Diabetes Obesity and Metabolism.
In The Last Decade
W. Zhang
18 papers receiving 350 citations
Peers
W. Zhang
Christopher J. Darus United States
Risu Na China
Juyong Liang China
Yukari Ishiguro Japan
Ancheng Qin China
Hwei‐Ming Wang Taiwan
Xiju Wang China
Bojian Xie China
Alessandra Cocomazzi Italy
L. Hart United States
Citations per year, relative to W. Zhang W. Zhang (= 1×)
peers
Christopher J. Darus
Countries citing papers authored by W. Zhang
Since
Specialization
Citations
This map shows the geographic impact of W. Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Zhang more than expected).
Fields of papers citing papers by W. Zhang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by W. Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Zhang. The network helps show where W. Zhang may publish in the future.
Co-authorship network of co-authors of W. Zhang
This figure shows the co-authorship network connecting the top 25 collaborators of W. Zhang. A scholar is included among the top collaborators of W. Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Zhang. W. Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Berger, Martin D., Sebastian Stintzing, Volker Heinemann, et al.. (2018). Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. Annals of Oncology. 29. viii18–viii18.
2.
Berger, Martin D., Sebastian Stintzing, Volker Heinemann, et al.. (2017). Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology. 28(11). 2780–2785.
3.
Sunakawa, Yu, Sebastian Stintzing, Shu Cao, et al.. (2015). Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Annals of Oncology. 26(12). 2450–2456.
4.
Stremitzer, Stefan, W. Zhang, Dongyun Yang, et al.. (2015). Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Annals of Oncology. 26(8). 1728–1733.
5.
Stremitzer, Stefan, Anna S. Berghoff, W. Zhang, et al.. (2015). Genetic variants associated with colorectal brain metastases susceptibility and survival. The Pharmacogenomics Journal. 17(1). 29–35.
6.
Sunakawa, Yu, Stefan Stremitzer, Shu Cao, et al.. (2014). Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Annals of Oncology. 26(2). 332–339.
7.
Absenger, Gudrun, Léonor Benhaïm, Joanna Szkandera, et al.. (2013). The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. The Pharmacogenomics Journal. 14(2). 130–134.
8.
Kasichayanula, Sreeneeranj, Xuejun Liu, W. Zhang, et al.. (2011). Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obesity and Metabolism. 13(8). 770–773.
9.
LaBonte, Melissa J., P. M. Wilson, Dongyun Yang, et al.. (2011). The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Annals of Oncology. 23(6). 1455–1464.
10.
El-Khoueiry, Anthony B., Ramesh K. Ramanathan, Dongyun Yang, et al.. (2011). A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investigational New Drugs. 30(3). 1175–1183.
11.
Winder, Thomas, Georgios Giamas, W. Zhang, et al.. (2011). Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients.. Journal of Clinical Oncology. 29(15_suppl). 538–538.
12.
Gerger, Armin, W. Zhang, Pierre Bohanes, et al.. (2011). Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). 3592–3592.
13.
Kasichayanula, Sreeneeranj, Xuejun Liu, W. Zhang, et al.. (2010). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obesity and Metabolism. 13(1). 47–54.
14.
Lurje, Georg, Hatim Husain, Derek G. Power, et al.. (2009). Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Annals of Oncology. 21(1). 78–86.
15.
Winder, Thomas, W. Zhang, Anthony B. El-Khoueiry, et al.. (2009). Association of a germ-line variant in the K-ras 3’ untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. Journal of Clinical Oncology. 27(15_suppl). 4061–4061.
16.
Zhang, W., Dongyun Yang, Georg Lurje, et al.. (2009). Association of CD133 polymorphisms and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with either first-line 5-FU + bevacizumab (BV) or second-line irinotecan (IR)/cetuximab (CB) or IR alone. Journal of Clinical Oncology. 27(15_suppl). 4062–4062.
17.
Yang, Dongyun, W. Zhang, Georg Lurje, et al.. (2009). Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/− cetuximab (CB): The EPIC experience. Journal of Clinical Oncology. 27(15_suppl). 4022–4022.
18.
Chang, Heung-Moon, Dongyun Yang, Jabi E. Shriki, et al.. (2007). Polymorphisms in angiogenesis related genes predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). Journal of Clinical Oncology. 25(18_suppl). 10576–10576.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christopher J. Darus Breakdown of academic impact, for papers by Risu Na Breakdown of academic impact, for papers by Juyong Liang Breakdown of academic impact, for papers by Yukari Ishiguro Breakdown of academic impact, for papers by Ancheng Qin Breakdown of academic impact, for papers by Hwei‐Ming Wang Breakdown of academic impact, for papers by Xiju Wang Breakdown of academic impact, for papers by Bojian Xie Breakdown of academic impact, for papers by Alessandra Cocomazzi Breakdown of academic impact, for papers by L. Hart